First-ever medicine designed and discovered by AI enters human trials
Image Credit: analyticsvidhya
A new drug, the first to be designed completely with the help of AI, is now entering into phase 2 clinical trials. This medicine—developed by Hong Kong-based Insilico Medicine—is targeted at a rare chronic lung disease called idiopathic pulmonary fibrosis (IPF) which affects millions worldwide. IPF, characterized by progressive lung fibrosis and breathing problems, has no cure as of now.